Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3239-3250

  Bunn P A , Jr ^a   Helfrich, B ^a   Soriano, A F ^a   Franklin, W A ^a   Varella Garcia, M ^a   Hirsch, F R ^a   Baron, A ^a   Zeng, C ^a   Chan, D C ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; ONCOPROTEIN; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DIVISION; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PACLITAXEL; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0034787857     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cancer statistics 2000
2. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
3. Genetic mechanisms of solid tumor oncogenesis
4. Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients
5. p185neu expression in human lung carcinomas predicts shortened survival
6. Multiple molecular marker testing (p53, c-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curable resected non-small cell lung cancer
7. HER-2/neu expression in archival non-small cell lung carcinoma using FDA-approved Hercep test
8. Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel, carboplatin and trastuzmab in HER2/neu + advanced NSCLC: Preliminary analysis
9. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma
10. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of the lung
11. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
12. c-erb-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas
13. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
14. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities
15. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
16. ErbB tyrosine kinases and the two neuregulin families constitute a ligand receptor network
17. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand
18. HER2 gene amplification by fluorescence in situ hybridization allows risk group assessment in node negative breast cancer
19. The concordance between the clinical trials assays (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials
20. Evaluation of HER2/neu expression in lung cancer tumors by immunohistochemistry and fluorescence in situ hybridization
21. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancers
22. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER2/neu gene expression but not with fas gene mutations
23. Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
24. Addition of herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anti-cancer activity
25. Recombinant anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
26. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung
27. Chemosensitivity testing of human lung cancer cell lines using the MTT assay
28. Analysis of combined drug effects: A new look at a very old problem
29. A new flow cytometric method for quantitative assessment of lymphocyte mitogenic potentials
30. Randomized phase II trial comparing trastuzumab plus weekly docetaxel versus trastuzmab plus weekly paclitaxel in previously untreated advanced non-small cell lung cancer